Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover study of subcutaneous MK-3475A vs intravenous pembrolizumab in solid tumors (Japan)
jRCT2051230147Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in cutaneous melanoma (CM), renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Participant preference. Started Dec 2023; status: completed.
02
Drugs
03
Conditions
cutaneous melanoma (CM)renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051230147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230147.